ǰÑÔ
Ö¬·¾¸Î(fatty liver disease,FLD)ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔÓÉÒýÆðµÄ¸ÎÔàÖ¬·¾´úлÕϰ£¬Ö¬ÀàÎïÖʵĶ¯Ì¬Æ½ºâʧµ÷£¬¸Îϸ°ûÄÚÖ¬·¾Èº¼¯¹ý¶àµÄ²¡±ä¡£Ö¬·¾¸ÎµÄ·¢²¡ÂʽüÄêÀ´Ñ¸ËÙÉÏÉý£¬ÒѳÉΪ½ö´ÎÓÚ²¡¶¾ÐÔ¸ÎÑ׵ĵڶþ´ó¸Î²¡£¬ÕýÑÏÖØÍþв¹úÈ˵Ŀµ½¡¡£Æ¾Ö¤²¡Òò£¬Ö¬·¾¸Î¿É·ÖΪ·Ç¾Æ¾«ÐԺ;ƾ«ÐÔÁ½´óÀà¡£·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡(nonalcoholic fatty liver disease, NAFLD)·¢²¡»úÖÆÏÖÔÚÉÐδÃ÷È·£¬ÖÎÁÆÉÏҲȱ·¦ÓÐÓò½·¥£¬ÊÇÏÖÔÚÑо¿µÄÖØµã¡£¾Æ¾«ÐÔÖ¬·¾¸Î¶¯ÎïÄ£×ÓÒÔÒûʳÓÕµ¼ÎªÖ÷£¬¾Æ¾«¿Éʹ¶¯Îï¸ÎÔàÑõÏûºÄÂÊÔö¸ß£¬ÔöÌíѪñ¼ÑªµÄÑõÏûºÄ£¬´Ó¶øïÔ̶ÔСҶÖÐÐĸÎϸ°ûµÄÑõ¹©£¬ÒýÆð¸ÃÇøÓòµÄ¸Îϸ°ûÍË»¯Ó뻵ËÀ£¬²¢±¬·¢Ö¬·¾±äÐÔ¡£ÀíÏëµÄÖ¬·¾¸Î¶¯ÎïÄ£×ÓÓ¦ÓëÈËÀàÖ¬·¾ÐԸβ¡µÄÌØÕ÷ÏàËÆ£¬¼´²¡±äÉú³¤Àú³ÌÓÐÏà¶ÔÏÔ×ÅµÄ·ÖÆÚ£¬´Ó´¿´âÐÔÖ¬·¾¸Î¡¢Ö¬·¾ÐÔ¸ÎÑס¢¸ÎÏËά»¯ÖÁ¸ÎÓ²»¯£¬²¢ÇÒÓ¦¾ßÓÐÄ£×ÓÐγÉÂʸߡ¢éæÃüÂʵ͡¢ÔìÄ£ÒªÁìÇáÓ¯Ò×ÐС¢¶ÔʵÑéÖ°Ô±ÎÞº¦¡¢ÔìÄ£×èÖ¹ºó²¡±äÄæ×ª»ºÂý£¬±ãÓÚ¾ÙÐÐÒ©Îï¸ÉÔ¤ÊÔÑéµÈÌØµã¡£ÏÖÔÚÒѾÔÚ´óÊó¡¢É³Êó¡¢Ð¡Êó¡¢¼ÒÍúÍÖíµÈ¶¯ÎïÖÖÊôÀֳɵؽ¨ÉèÁËÖ¬·¾¸Î¶¯ÎïÄ£×Ó£¬ÕâЩ¶¯ÎïÄ£×ÓΪÃ÷È·Ö¬·¾¸Î·¢²¡»úÖÆ¡¢É¸Ñ¡Ò©ÎïµÈ»ù´¡ºÍÁÙ´²Ñо¿ÌṩÁ˺ܺõÄʵÑ鹤¾ß¡£
FLD¶¯ÎïÄ£×ÓÖ÷Òª·ÖΪËÄ´óÀࣺ×Ô¾õÐÔÄ£×Ó£¬»ùÒòÐÞÊζ¯ÎïÄ£×Ó£¬Òûʳ¡¢Ò©Îï»ò¶¾ÎïÓÕµ¼Ä£×Ó£¬¸´ºÏÄ£×Ó£¨ÍŽáÓ¦ÓûùÒòÄ£×ÓºÍÓªÑøÄ£×Ó£©¡£ËüÃÇÔÚ²î±ðµÄ²ãÃæÊ©Õ¹×÷Ó㬵«×îÖÕÖ÷ÒªÊÇͨ¹ýʹ¸ÎÔàÖ¬·¾ÊäÈ루ºÏ³É»òÉãÈ룩ÔöÌí»òÊä³ö£¨É¨³ý£©ïÔ̵ÄÔÀíÖÆ³É¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÓÉÓÚ¸Îϸ°ûÖ¬·¾´úлҪº¦»ùÒòµÄÍ»±ä£¬ÒýÆðÖ¬·¾´úлÔÓÂÒ£¬µ¼Ö¸ÎÔàÖ¬·¾ÊäÈëºÍÊä³öƽºâʧµ÷¡£
¡¾Ä£×ÓÌØµã¡¿£º
oh/obСÊó(ob/ob mice)ÊÇÓÉÃÀ¹úJacksonʵÑéÊÒÓÚ1949ÄêÎÞÒâ·¢Ã÷µÄ»ùÒòÒþÐÔÒÅ´«Í»±äСÊó£¬ÏÖÔÚÊÇÍâÑó×î³£ÓÃNAFLDÄ£×Ó¡£ob/obСÊóÊÇÓÉÓÚ±àÂëʳÓûÒÖÖÆ¼¤ËØleptinµÄob»ùÒò±¬·¢×Ô¾õÐÔÍ»±ä£¬ÎÞ·¨ºÏ³ÉÊÝËØ£¬µ¼ÖÂÌ«¹ýÉãʳ¡¢·ÊÅÖ£¬·ºÆð¸ßÒȵºËØÑªÖ¢¡¢¸ß֬Ѫ֢¼°ÏÔ×ŵĸßѪÌÇÖ¢¡£×éÖ¯²¡Àíѧ¸Ä±äΪ¸Îϸ°ûÖ¬·¾±äÐԵȣ¨Í¼7-2/ÎÄÄ©²Êͼ7-2)¡£Í¨Ë×ËÇÁÏËÇι½ö±¬·¢´¿´âÐÔÖ¬·¾¸Î£¬²»»áÑݱäΪ·Ç¾Æ¾«ÐÔÖ¬·¾ÐÔ¸ÎÑ×(nonalcoholic steatohepatitis,NASH)£¬³ý·Ç¸øÓèµ°°±ËáºÍµ¨¼îȱ·¦Òûʳ»ò¸ßÖ¬Òûʳ»ò²¢´æÆäËû¸ÎËðÉËÒòËØ¡£
db/dbСÊó»òfa/fa (Zucker)´óÊóÊÇÓÉÓÚÊÝËØÊÜÌåµÄdb»ùÒò£¨»òfa»ùÒò£©Í»±äÔì³É£¬µ¼ÖÂÁËÊÝËØ¶Ô¿¹£¬´Ó¶øÒýÆðÁËÓëob/obСÊóÏàËÆµÄ±íÐÍ¡£
FLSСÊó(fatty liver shionogi mouse)ÊÇSoga¼´ÊÇ1999Ä걨µÀµÄͨ¹ýͬϵ½»ÅäÒªÁ죬½¨ÉèÁËÒ»ÖÖÎÞÌ«¹ýÉãʳ¡¢²»·ºÆð·ÊÅÖºÍÌÇÄò²¡¶ø°éÓÐÖ¬·¾¸ÎµÄÐÂÆ·ÏµÐ¡Êó¡£ÐÂÉúFLSСÊóÈ«¸ÎСҶ¸Îϸ°ûÄÚ¼´ÓÐϸС֬·¾¿ÅÁ£Èº¼¯£¬²¢ËæÄêËêÔöÉϾÙÐÐÐÔ¼ÓÖØ£¬¸ÎÔà¸ÊÓÍÈýõ¥(triglyceride,TG)º¬Á¿½ÏͬÁädd Shionogi (DS)СÊóÉý¸ß5±¶£¬µ«ÑªÖ¬¶àÎÞÒì³£¡£2~4¸öÔÂFLSСÊó¸ÎÔàÄڿɼûµ¥ºËϸ°û½þÈ󼰳ɴØÅÝÄϸ°û·ºÆð£¬°éѪÇåת°±Ã¸Ë®Æ½Éý¸ß¡£4~6ÔÂÁäFLSСÊó¸Îϸ°ûÄÚ´óÖ¬µÎÊýÄ¿½ÏǰïÔÌ£¬12¸öÔÂFLSСÊóÒ×ÐγÉ×Ô¾õÐÔ¸Îϸ°ûÏÙÁö(hepatocellular adenoma,HCA)»ò¸Îϸ°û°©(hepatocellular carcinoma,HCC)¡£
7-2 ob/obСÊó¸ÎÔà¸ÅÂÔ¼°×é֯ѧͼƬ
×¢£ºA. ob/obСÊó¸ÎÔà(3¸öÔ£©£»B. ob/obСÊó×Ô¾õÖ¬·¾¸Î(3¸öÔ£©£»C. H&EȾɫÏÔʾob/obСÊóÕý³£¸ÎÔà×éÖ¯£» D.H&EȾɫÏÔʾob/obСÊó¸ÎÔàÓÐÖ¬·¾³Á»ý
²Î¿¼ÎÄÏ×£º
1.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉ磬2000
2.Farrell GC, van Rooyen D. Liver cholesterol: is ii playing possum in NASH? Am J Physiol Gastroinlesl Liver Physiol,2012,303 (1):G9-11
3.Maher JJ. New insights from rodent models of fatly liver disease. Anliox.id Redox Signal, 2011, 15 (2):535-550
4.Matsuzawa N,Takamura T, Kurita S, el al. Lipid-induced oxidative stress causes sleatohepalitis in, mice fed an atherogenic diet. Hepatology, 2007,46 (5):1392-1403
5.Sahai A, Malladi P, Pan X, el al. Obese and diabeti db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepalitis: role of sbortform leptin receptors and osteopontin. Am J Physiol Gastroinlest Liver Pbysiol, 2004,287 (5):Gl035-1043
6.Uno M, Kurita S, Misu H,et al. Tranilast,an anlifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepalitis. Hepatology, 2008, 48 (1) : 109-118
7.Xu Z,Chen L,Leung L,el al. Liver-specific i.naclivalion of the Nrfl gene in adult mouse leads lo nonalcoholic steatobepatilis and hepatic neoplasia. Proc Natl Acad Sci US A, 2005, 15; 102 (11):4120-4125